Extensive major histocompatibility complex class I binding promiscuity for Mycobacterium tuberculosis TB10.4 peptides and immune dominance of human leucocyte antigen (HLA)-B*0702 and HLA-B*0801 alleles in TB10.4 CD8+ T-cell responses

Immunology

Volumn 129, Issue 4, 2010, Pages 496-505

  Axelsson Robertson, Rebecca ^a   Weichold, Frank ^b   Sizemore, Donata ^b   Wulf, Markus ^c   Skeiky, Yasir A W ^b   Sadoff, Jerry ^b   Maeurer, Markus J ^a,d  

^a KAROLINSKA INSTITUTE   (Sweden)

^b Aeras Global TB Vaccine Foundation   (United States)

^c Thymed ^*  (Germany)

^d SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

Author keywords

CD8+ T cells; Epitopes; Immune dominance; Mycobacterium tuberculosis; TB10.4

Indexed keywords

ALANYLMETHIONYLGLUTAMYLASPARTYLLEUCYLVALYLARGINYLALANYLTYROSINE; ALANYLMETHIONYLLEUCYLGLYCYLHISTIDYLALANYLGLYCYLASPARTYLMETHIONINE; ARGINYLALANYLTYROSYLHISTIDYLALANYLMETHIONYLSERYLSERYLTHREONINE; ASPARTYLLEUCYLVALYLARGINYLALANYLMETHIONYLHISTIDYLALANYLMETHIONINE; ASPARTYLMETHIONYLALANYLGLYCYLTYROSYLALANYLGLYCYLTHREONYLLEUCINE; ASPARTYLTHREONYLGLYCYLISOLEUCYLTHREONYLTYROSYLGLUTAMINYLALANYLTRYPTOPHAN; BACTERIAL PROTEIN; EPITOPE; GLUTAMINYLALANYLMETHIONYLGLUTAMYLASPARTYLLEUCYLVALYLARGINYLALANINE; GLUTAMINYLISOLEUCYLMETHIONYLTYROSYLASPARAGINYLPROLYLALANYLMETHIONINE; GLUTAMINYLSERYLLEUCYLGLYCYLALANYLGLUTAMYLISOLEUCYLALANYLVALINE; GLYCYLISOLEUCYLTHREONYLTYROSYLGLUTAMINYLALANYLTRYPTOPHYLGLUTAMINYLALANINE; GLYCYLTYROSYLALANYLGLYCYLTHREONYLLEUCYLGLUTAMINYLSERYLLEUCINE; HISTIDYLALANYLMETHIONYLSERYLSERYLTHREONYLHISTIDYLGLUTAMYLALANINE; HLA B ANTIGEN; ISOLEUCYLMETHIONYLTYROSYLASPARAGINYLTYROSYLPROLYLALANYLMETHIONYLLEUCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; METHIONYLLEUCYLGLYCYLHISTIDYLALANYLGLYCYLASPARTYLMETHIONYLALANINE; METHIONYLSERYLGLUTAMINYLISOLEUCYLMETHIONYLTYROSYL ASPARAGINYLTYROSYLPROLINE; METHIONYLTYROSYLASPARAGINYLTYROSYLPROLYLALANYLMETHIONYLLEUCYLGLYCINE; SERYLALANYLTRYPTOPHYLGLUTAMINYLGLYCYLASPARTYLTHREONYLGLYCYLISOLEUCINE; SERYLGLUTAMINYLISOLEUCYLMETHIONYLTYROSYLASPARAGINYLTYROSYLPROLYLALANINE; SERYLLEUCYLGLYCYLALANYLGLUTAMYLISOLEUCYLALANYLVALYLGLUTAMIC ACID; TETRAMER; THREONYLLEUCYLGLUTAMINYLSERYLLEUCYLGLYCYLALANYLGLUTAMYLISOLEUCINE; THREONYLTYROSYLGLUTAMINYLALANYLTRYPTOPHYLGLUTAMINYLALANYL GLUTAMINYLTRYPTOPHAN; TRYPTOPHYLGLUTAMINYLALANYLGLUTAMINYLTRYPTOPHYLASPARAGINYL GLUTAMINYLALANYLMETHIONINE; TRYPTOPHYLGLUTAMINYLGLYCYLASPARTYLTHREONYLGLYCYLISOLEUCYLTHREONYLTYROSINE; TYROSYLGLUTAMINYLALANYLTRYPTOPHYLGLUTAMINYLALANYLGLUTAMINYL TRYPTOPHYLASPARAGINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALLELE; AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ARTICLE; CAUCASIAN; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; HUMAN; HUMAN CELL; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN MOTIF; SPECIES;

ALLELES; BINDING SITES; CD8-POSITIVE T-LYMPHOCYTES; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA-B ANTIGENS; HUMANS; MYCOBACTERIUM TUBERCULOSIS; PEPTIDES; TUBERCULOSIS, PULMONARY;

EID: 77949409919     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/j.1365-2567.2009.03201.x     Document Type: Article

References (42)

1. Flynn JL, Chan J. Immunology of tuberculosis. Annu Rev Immunol 2001; 19:93-129.
2. Lazarevic V, Flynn J. CD8+ T cells in tuberculosis. Am J Respir Crit Care Med 2002; 166:1116-21.
3. Behar SM, Woodworth JS, Wu Y. Next generation: tuberculosis vaccines that elicit protective CD8+ T cells. Expert Rev Vaccines 2007; 6:441-56.
4. Dietrich J, Weldingh K, Andersen P. Prospects for a novel vaccine against tuberculosis. Vet Microbiol 2006; 112:163-9.
5. Wu LC, Tuot DS, Lyons DS, Garcia KC, Davis MM. Two-step binding mechanism for T-cell receptor recognition of peptide MHC. Nature 2002; 418:552-6.
6. Prlic M, Hernandez-Hoyos G, Bevan MJ. Duration of the initial TCR stimulus controls the magnitude but not functionality of the CD8+ T cell response. J Exp Med 2006; 203:2135-43.
7. Kaech SM, Ahmed R. Memory CD8+ T cell differentiation: initial antigen encounter triggers a developmental program in naive cells. Nat Immunol 2001; 2:415-22.
8. Iezzi G, Karjalainen K, Lanzavecchia A. The duration of antigenic stimulation determines the fate of naive and effector T cells. Immunity 1998; 8:89-95.
9. Kaufmann SH. Recent findings in immunology give tuberculosis vaccines a new boost. Trends Immunol 2005; 26:660-7.
10. Lalvani A, Brookes R, Wilkinson RJ et al. Human cytolytic and interferon gamma-secreting CD8+ T lymphocytes specific for Mycobacterium tuberculosis. Proc Natl Acad Sci U S A 1998; 95:270-5.
11. Geluk A, van Meijgaarden KE, Franken KL, Drijfhout JW, D'Souza S, Necker A, Huygen K, Ottenhoff TH. Identification of major epitopes of Mycobacterium tuberculosis AG85B that are recognized by HLA-A*0201-restricted CD8+ T cells in HLA-transgenic mice and humans. J Immunol 2000; 165:6463-71.
12. Dietrich J, Aagaard C, Leah R, Olsen AW, Stryhn A, Doherty TM, Andersen P. Exchanging ESAT6 with TB10.4 in an Ag85B fusion molecule-based tuberculosis subunit vaccine: efficient protection and ESAT6-based sensitive monitoring of vaccine efficacy. J Immunol 2005; 174:6332-9.
13. Radosevic K, Wieland CW, Rodriguez A et al. Protective immune responses to a recombinant adenovirus type 35 tuberculosis vaccine in two mouse strains: CD4 and CD8 T-cell epitope mapping and role of gamma interferon. Infect Immun 2007; 75:4105-15.
14. Skjot RL, Brock I, Arend SM, Munk ME, Theisen M, Ottenhoff TH, Andersen P. Epitope mapping of the immunodominant antigen TB10.4 and the two homologous proteins TB10.3 and TB12.9, which constitute a subfamily of the esat-6 gene family. Infect Immun 2002; 70:5446-53.
15. Skjot RL, Oettinger T, Rosenkrands I, Ravn P, Brock I, Jacobsen S, Andersen P. Comparative evaluation of low-molecular-mass proteins from Mycobacterium tuberculosis identifies members of the ESAT-6 family as immunodominant T-cell antigens. Infect Immun 2000; 68:214-20.
16. Majlessi L, Rojas MJ, Brodin P, Leclerc C. CD8+-T-cell responses of Mycobacterium-infected mice to a newly identified major histocompatibility complex class I-restricted epitope shared by proteins of the ESAT-6 family. Infect Immun 2003; 71:7173-7.
17. Billeskov R, Vingsbo-Lundberg C, Andersen P, Dietrich J. Induction of CD8 T cells against a novel epitope in TB10.4: correlation with mycobacterial virulence and the presence of a functional region of difference-1. J Immunol 2007; 179:3973-81.
18. Middleton D, Menchaca L, Rood H, Komerofsky R. New allele frequency database: http://www.allelefrequencies.net. Tissue Antigens 2003; 61:403-7.
19. Weichold FF, Mueller S, Kortsik C, Hitzler WE, Wulf MJ, Hone DM, Sadoff JC, Maeurer MJ. Impact of MHC class I alleles on the M. tuberculosis antigen-specific CD8+ T-cell response in patients with pulmonary tuberculosis. Genes Immun 2007; 8:334-43.
20. Shingler WH, Chikoti P, Kingsman SM, Harrop R. Identification and functional validation of MHC class I epitopes in the tumor-associated antigen 5T4. Int Immunol 2008; 20:1057-66.
21. Bachinsky MM, Guillen DE, Patel SR, Singleton J, Chen C, Soltis DA, Tussey LG. Mapping and binding analysis of peptides derived from the tumor-associated antigen survivin for eight HLA alleles. Cancer Immun 2005; 5:6.
22. Britten CM, Janetzki S, Ben-Porat L et al. Harmonization guidelines for HLA-peptide multimer assays derived from results of a large scale international proficiency panel of the Cancer Vaccine Consortium. Cancer Immunol Immunother 2009; 58:1701-13.
23. Kamath A, Woodworth JS, Behar SM. Antigen-specific CD8+ T cells and the development of central memory during Mycobacterium tuberculosis infection. J Immunol 2006; 177:6361-9.
24. Falk K, Rotzschke O, Stevanovic S, Jung G, Rammensee HG. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. 1991. J Immunol 2006; 177: 2741-7.
25. Sette A, Sidney J. Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism. Immunogenetics 1999; 50:201-12.
26. Sabbaj S, Bansal A, Ritter GD et al. Cross-reactive CD8+ T cell epitopes identified in US adolescent minorities. J Acquir Immune Defic Syndr 2003; 33:426-38.
27. Masemola AM, Mashishi TN, Khoury G et al. Novel and promiscuous CTL epitopes in conserved regions of Gag targeted by individuals with early subtype C HIV type 1 infection from southern Africa. J Immunol 2004; 173:4607-17.
28. Frahm N, Yusim K, Suscovich TJ et al. Extensive HLA class I allele promiscuity among viral CTL epitopes. Eur J Immunol 2007; 37:2419-33.
29. Nakagawa M, Kim KH, Gillam TM, Moscicki AB. HLA class I binding promiscuity of the CD8 T-cell epitopes of human papillomavirus type 16 E6 protein. J Virol 2007; 81:1412-23.
30. Musser JM, Amin A, Ramaswamy S. Negligible genetic diversity of mycobacterium tuberculosis host immune system protein targets: evidence of limited selective pressure. Genetics 2000; 155:7-16.
31. Sette A, Vitiello A, Reherman B et al. The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J Immunol 1994; 153:5586-92.
32. Bihl F, Frahm N, Di Giammarino L et al. Impact of HLA-B alleles, epitope binding affinity, functional avidity, and viral coinfection on the immunodominance of virus-specific CTL responses. J Immunol 2006; 176:4094-101.
33. Rao X, Costa AI, van Baarle D, Kesmir C. A comparative study of HLA binding affinity and ligand diversity: implications for generating immunodominant CD8+ T cell responses. J Immunol 2009; 182:1526-32.
34. Tenzer S, Wee E, Burgevin A et al. Antigen processing influences HIV-specific cytotoxic T lymphocyte immunodominance. Nat Immunol 2009; 10:636-46.
35. Yewdell JW, Bennink JR. Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. Annu Rev Immunol 1999; 17:51-88.
36. Tully G, Kortsik C, Hohn H et al. Highly focused T cell responses in latent human pulmonary Mycobacterium tuberculosis infection. J Immunol 2005; 174:2174-84.
37. Hohn H, Kortsik C, Tully G et al. Longitudinal analysis of Mycobacterium tuberculosis 19-kDa antigen-specific T cells in patients with pulmonary tuberculosis: association with disease activity and cross-reactivity to a peptide from HIVenv gp120. Eur J Immunol 2003; 33:1613-23.
38. Lewinsohn DA, Winata E, Swarbrick GM et al. Immunodominant tuberculosis CD8 antigens preferentially restricted by HLA-B. PLoS Pathog 2007; 3:1240-9.
39. Kiepiela P, Leslie AJ, Honeyborne I et al. Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA. Nature 2004; 432:769-75.
40. Lacey SF, Villacres MC, La Rosa C et al. Relative dominance of HLA-B*07 restricted CD8+ T-lymphocyte immune responses to human cytomegalovirus pp65 in persons sharing HLA-A*02 and HLA-B*07 alleles. Hum Immunol 2003; 64:440-52.
41. Seitzer U, Kayser K, Hohn H et al. Reduced T-cell receptor CD3zeta-chain protein and sustained CD3epsilon expression at the site of mycobacterial infection. Immunology 2001; 104:269-77.
42. Daley CL, Hahn JA, Moss AR, Hopewell PC, Schecter GF. Incidence of tuberculosis in injection drug users in San Francisco: impact of anergy. Am J Respir Crit Care Med 1998; 157:19-22.